Construction and characterization of a thrombin-resistant designer FGF-based collagen binding domain angiogen

Luke P. Brewster, Cicely Washington, Eric M. Brey, Andrew Gassman, Anuradha Subramanian, Jen Calceterra, William Wolf, Connie L. Hall, William H Velander, Wilson H. Burgess, Howard P. Greisler

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Humans demonstrate limited spontaneous endothelialization of prosthetic bypass grafts. However the local application of growth factors to prosthetic grafts or to injured blood vessels can provide an immediate effect on endothelialization. Novel chimeric proteins combining potent angiogens with extracellular matrix binding domains may localize to exposed matrices and provide sustained activity to promote endothelial regeneration after vascular interventions. We have ligated a thrombin-resistant mutant of fibroblast growth factor (FGF)-1 (R136K) with a collagen binding domain (CBD) in order to direct this growth factor to sites of exposed vascular collagen or selected bioengineered scaffolds. While FGF-1 and R136K are readily attracted to a variety of matrix proteins, R136K-CBD demonstrated selective and avid binding to collagen ∼4x that of FGF-1 or R136K alone (P<0.05). The molecular stability of R136K-CBD was superior to FGF-1 and R136K. Its chemotactic activity was superior to R136K and FGF-1 (11±1% vs. 6±2% and 4±1%; P<0.01). Its angiogenic activity was similar to R136K and significantly greater than control by day 2 (P<0.01). After day 3, FGF-1-treated endothelial cell's (EC) sprouts had regressed back to levels insignificant compared to the control group (P=0.17), while both R136K and R136K-CBD continued to demonstrate greater sprout lengthening as compared to control (P<0.0002). The mitogenic activity of all growth factors was greater than control groups (20% PBS); in all comparisons (P<0.0001). This dual functioning angiogen provides proof of concept for the application of designer angiogens to matrix binding proteins to intelligently promote endothelial regeneration of selected matrices.

Original languageEnglish (US)
Pages (from-to)327-336
Number of pages10
JournalBiomaterials
Volume29
Issue number3
DOIs
StatePublished - Jan 1 2008

Fingerprint

Fibroblast Growth Factor 1
Fibroblast Growth Factors
Fibroblasts
Collagen
Thrombin
Blood Vessels
Intercellular Signaling Peptides and Proteins
Prosthetics
Grafts
Regeneration
Transplants
Control Groups
Endothelial cells
Blood vessels
Scaffolds
Proteins
Extracellular Matrix
succinic acid drug combination aspirin
Carrier Proteins
Endothelial Cells

Keywords

  • Angiogenesis
  • Collagen
  • Endothelial cell
  • Endothelialization
  • Fibroblast growth factor
  • Growth factors

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering

Cite this

Construction and characterization of a thrombin-resistant designer FGF-based collagen binding domain angiogen. / Brewster, Luke P.; Washington, Cicely; Brey, Eric M.; Gassman, Andrew; Subramanian, Anuradha; Calceterra, Jen; Wolf, William; Hall, Connie L.; Velander, William H; Burgess, Wilson H.; Greisler, Howard P.

In: Biomaterials, Vol. 29, No. 3, 01.01.2008, p. 327-336.

Research output: Contribution to journalArticle

Brewster, LP, Washington, C, Brey, EM, Gassman, A, Subramanian, A, Calceterra, J, Wolf, W, Hall, CL, Velander, WH, Burgess, WH & Greisler, HP 2008, 'Construction and characterization of a thrombin-resistant designer FGF-based collagen binding domain angiogen', Biomaterials, vol. 29, no. 3, pp. 327-336. https://doi.org/10.1016/j.biomaterials.2007.09.034
Brewster, Luke P. ; Washington, Cicely ; Brey, Eric M. ; Gassman, Andrew ; Subramanian, Anuradha ; Calceterra, Jen ; Wolf, William ; Hall, Connie L. ; Velander, William H ; Burgess, Wilson H. ; Greisler, Howard P. / Construction and characterization of a thrombin-resistant designer FGF-based collagen binding domain angiogen. In: Biomaterials. 2008 ; Vol. 29, No. 3. pp. 327-336.
@article{f5203a121b4c43bdb99814a2d36e9dc8,
title = "Construction and characterization of a thrombin-resistant designer FGF-based collagen binding domain angiogen",
abstract = "Humans demonstrate limited spontaneous endothelialization of prosthetic bypass grafts. However the local application of growth factors to prosthetic grafts or to injured blood vessels can provide an immediate effect on endothelialization. Novel chimeric proteins combining potent angiogens with extracellular matrix binding domains may localize to exposed matrices and provide sustained activity to promote endothelial regeneration after vascular interventions. We have ligated a thrombin-resistant mutant of fibroblast growth factor (FGF)-1 (R136K) with a collagen binding domain (CBD) in order to direct this growth factor to sites of exposed vascular collagen or selected bioengineered scaffolds. While FGF-1 and R136K are readily attracted to a variety of matrix proteins, R136K-CBD demonstrated selective and avid binding to collagen ∼4x that of FGF-1 or R136K alone (P<0.05). The molecular stability of R136K-CBD was superior to FGF-1 and R136K. Its chemotactic activity was superior to R136K and FGF-1 (11±1{\%} vs. 6±2{\%} and 4±1{\%}; P<0.01). Its angiogenic activity was similar to R136K and significantly greater than control by day 2 (P<0.01). After day 3, FGF-1-treated endothelial cell's (EC) sprouts had regressed back to levels insignificant compared to the control group (P=0.17), while both R136K and R136K-CBD continued to demonstrate greater sprout lengthening as compared to control (P<0.0002). The mitogenic activity of all growth factors was greater than control groups (20{\%} PBS); in all comparisons (P<0.0001). This dual functioning angiogen provides proof of concept for the application of designer angiogens to matrix binding proteins to intelligently promote endothelial regeneration of selected matrices.",
keywords = "Angiogenesis, Collagen, Endothelial cell, Endothelialization, Fibroblast growth factor, Growth factors",
author = "Brewster, {Luke P.} and Cicely Washington and Brey, {Eric M.} and Andrew Gassman and Anuradha Subramanian and Jen Calceterra and William Wolf and Hall, {Connie L.} and Velander, {William H} and Burgess, {Wilson H.} and Greisler, {Howard P.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1016/j.biomaterials.2007.09.034",
language = "English (US)",
volume = "29",
pages = "327--336",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Construction and characterization of a thrombin-resistant designer FGF-based collagen binding domain angiogen

AU - Brewster, Luke P.

AU - Washington, Cicely

AU - Brey, Eric M.

AU - Gassman, Andrew

AU - Subramanian, Anuradha

AU - Calceterra, Jen

AU - Wolf, William

AU - Hall, Connie L.

AU - Velander, William H

AU - Burgess, Wilson H.

AU - Greisler, Howard P.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Humans demonstrate limited spontaneous endothelialization of prosthetic bypass grafts. However the local application of growth factors to prosthetic grafts or to injured blood vessels can provide an immediate effect on endothelialization. Novel chimeric proteins combining potent angiogens with extracellular matrix binding domains may localize to exposed matrices and provide sustained activity to promote endothelial regeneration after vascular interventions. We have ligated a thrombin-resistant mutant of fibroblast growth factor (FGF)-1 (R136K) with a collagen binding domain (CBD) in order to direct this growth factor to sites of exposed vascular collagen or selected bioengineered scaffolds. While FGF-1 and R136K are readily attracted to a variety of matrix proteins, R136K-CBD demonstrated selective and avid binding to collagen ∼4x that of FGF-1 or R136K alone (P<0.05). The molecular stability of R136K-CBD was superior to FGF-1 and R136K. Its chemotactic activity was superior to R136K and FGF-1 (11±1% vs. 6±2% and 4±1%; P<0.01). Its angiogenic activity was similar to R136K and significantly greater than control by day 2 (P<0.01). After day 3, FGF-1-treated endothelial cell's (EC) sprouts had regressed back to levels insignificant compared to the control group (P=0.17), while both R136K and R136K-CBD continued to demonstrate greater sprout lengthening as compared to control (P<0.0002). The mitogenic activity of all growth factors was greater than control groups (20% PBS); in all comparisons (P<0.0001). This dual functioning angiogen provides proof of concept for the application of designer angiogens to matrix binding proteins to intelligently promote endothelial regeneration of selected matrices.

AB - Humans demonstrate limited spontaneous endothelialization of prosthetic bypass grafts. However the local application of growth factors to prosthetic grafts or to injured blood vessels can provide an immediate effect on endothelialization. Novel chimeric proteins combining potent angiogens with extracellular matrix binding domains may localize to exposed matrices and provide sustained activity to promote endothelial regeneration after vascular interventions. We have ligated a thrombin-resistant mutant of fibroblast growth factor (FGF)-1 (R136K) with a collagen binding domain (CBD) in order to direct this growth factor to sites of exposed vascular collagen or selected bioengineered scaffolds. While FGF-1 and R136K are readily attracted to a variety of matrix proteins, R136K-CBD demonstrated selective and avid binding to collagen ∼4x that of FGF-1 or R136K alone (P<0.05). The molecular stability of R136K-CBD was superior to FGF-1 and R136K. Its chemotactic activity was superior to R136K and FGF-1 (11±1% vs. 6±2% and 4±1%; P<0.01). Its angiogenic activity was similar to R136K and significantly greater than control by day 2 (P<0.01). After day 3, FGF-1-treated endothelial cell's (EC) sprouts had regressed back to levels insignificant compared to the control group (P=0.17), while both R136K and R136K-CBD continued to demonstrate greater sprout lengthening as compared to control (P<0.0002). The mitogenic activity of all growth factors was greater than control groups (20% PBS); in all comparisons (P<0.0001). This dual functioning angiogen provides proof of concept for the application of designer angiogens to matrix binding proteins to intelligently promote endothelial regeneration of selected matrices.

KW - Angiogenesis

KW - Collagen

KW - Endothelial cell

KW - Endothelialization

KW - Fibroblast growth factor

KW - Growth factors

UR - http://www.scopus.com/inward/record.url?scp=35848968897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35848968897&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2007.09.034

DO - 10.1016/j.biomaterials.2007.09.034

M3 - Article

VL - 29

SP - 327

EP - 336

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 3

ER -